Comparative evaluation of immunization with recombinant protein and plasmid DNA vaccines of fusion antigen ROP2 and SAG1 from Toxoplasma gondii in mice: cellular and humoral immune responses
Authors:
- 15 March 2011
- journal article
- Published by Springer Nature in Parasitology Research
- Vol. 109 (3) , 637-644
Abstract
The aim of this work was to evaluate immune responses in BALB/c mice vaccinated subcutaneously by recombinant protein, or intramuscularly by plasmid DNA with fusion antigen of rhoptry protein 2 (ROP2) and major surface protein 1 (SAG1) from Toxoplasma gondii (T. gondii). BALB/c mice were immunized with one of three different antigen formulations respectively, which were rROP2-SAG1, pcROP2-SAG1, and pcROP2-SAG1 boosted with rROP2-SAG1. The production of IgG, IgG subclasses, lymphoproliferation, and level of gamma interferon (IFN-γ) were detected after vaccination. The animals vaccinated with rROP2-SAG1 quickly developed specific anti-TLA (T. gondii lysate antigen) antibodies, which continued to rise after immunization. However, production of IgG against TLA in mice vaccinated with pcROP2-SAG1 was relatively slow and maintained a high level after reaching plateau. There are more vigorous specific lymphoproliferative responses observed in mice of group rROP2-SAG1 than in pcROP2-SAG1. Immune responses in mice of group pcROP2-SAG1 boosted with rROP2-SAG1 were similar to the protein immunization group. Three immunization procedures resulted in a similar level of IFN-γ production. Our results indicate that BALB/c mice vaccinated by three immunization procedures induce similar humoral and cellular immunity against infection of T. gondii. Mice immunized with recombinant protein rROP2-SAG1 produce more humoral immune responses than mice immunized with other antigen formulations.Keywords
This publication has 26 references indexed in Scilit:
- Construction and immunogenicity of pseudotype baculovirus expressing Toxoplasma gondii SAG1 protein in BALB/c mice modelVaccine, 2010
- Azurin-Like Protein Blocks Invasion ofToxoplasma gondiithrough Potential Interactions with Parasite Surface Antigen SAG1Antimicrobial Agents and Chemotherapy, 2008
- Vaccination as a control strategy against the coccidial parasitesEimeria,ToxoplasmaandNeosporaParasitology, 2006
- Chimeric Antigens ofToxoplasma gondii: Toward Standardization of Toxoplasmosis Serodiagnosis Using Recombinant ProductsJournal of Clinical Microbiology, 2006
- Potent antigen-specific immunity to Toxoplasma gondii in adjuvant-free vaccination system using Rop2-Leishmania infantum Hsp83 fusion proteinVaccine, 2006
- Usefulness of Toxoplasma gondii -Specific Recombinant Antigens in Serodiagnosis of Human ToxoplasmosisJournal of Clinical Microbiology, 2004
- Protective Immunity against Congenital Toxoplasmosis with Recombinant SAG1 Protein in a Guinea Pig ModelInfection and Immunity, 2000
- Immunization with a DNA Plasmid Encoding the SAG1 (P30) Protein ofToxoplasma gondiiIs Immunogenic and Protective in RodentsThe Journal of Infectious Diseases, 2000
- Vaccination with HIV-1 gp120 DNA induces immune responses that are boosted by a recombinant gp120 protein subunitVaccine, 1997
- Nucleic acid vaccination of sheep: Use in combination with a conventional adjuvanted vaccine against Taenia ovisImmunology & Cell Biology, 1997